Alternatives to Pairx

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing novel therapeutics targeting dysfunctional DNA packaging for diseases like cancer.

Biotechnology company advancing novel therapeutics using its proprietary LEADS drug discovery platform.

AI-driven drug discovery spinoff from DeepMind using AlphaFold to discover novel medicines.

Global CRDMO providing integrated R&D and manufacturing services for the pharmaceutical and life sciences industries.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Biopharmaceutical company developing T-cell therapies for solid tumor cancers.

Clinical-stage biopharma developing precisely designed cancer therapeutics using a proprietary cell-free protein synthesis platform.

A global contract research organization specializing in preclinical and translational oncology research.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

AI-guided drug discovery platform for tissue-targeted medicines.

Biopharmaceutical company developing novel therapeutics for cancer and other diseases using chemoproteomics and covalent chemistry.

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Developing engineered biologics to harness the immune system for disease treatment.

Developing microbiome-derived therapies to overcome resistance to immune checkpoint inhibitors in cancer treatment.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

Develops antibody-drug conjugates (ADCs) for targeted cancer therapy.

BreezeBio is a genetic medicine company developing a pipeline of precision therapeutics.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

Precision oncology company developing cancer therapies guided by proprietary functional genomics.

Biotechnology company specializing in antibody discovery and protein engineering for therapeutic applications.

A clinical-stage oncology company developing DNA interference (DNAi) based cancer therapies.

Engineering scalable gene therapies for broader patient populations.

AI-powered antibody discovery platform.

AI-native biotech company designing next-generation CAR T therapies for solid tumors.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

Global biopharmaceutical company specializing in plasma-derived therapeutics for rare and serious conditions.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on oncology drug discovery.

Physics-based software platform for molecular discovery and design in life and materials sciences.

Immunotherapy company targeting oncology and autoimmune diseases.

Pioneering precision microbiome therapeutics for oncology using CRISPR and synthetic biology.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Scalable, one-time curative in-vivo gene editing therapies.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Global leader in enzymatic therapeutics for non-surgical tissue repair, replacing existing standards of care.

A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.

Developing a new histotripsy therapeutic platform for cancer treatment.

Advancing targeted alpha therapies.

South Korean biopharmaceutical company developing novel biologics for cancer and rare diseases.

Clinical-stage biopharmaceutical company developing novel boron-based small molecule therapeutics for rare infectious diseases and oncology.

Developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform for solid tumors.

Developing a novel small molecule inhibitor for ovarian cancer treatment targeting DIO3.

AI drug discovery startup that learns directly from patient biology to identify and design novel medicines, focusing on oncology and fibrosis.

Engineering-driven DNA design platform to overcome biological barriers in genetic medicines.

Clinical-stage biotech company developing transformative cytokine therapies.

Clinical-stage oncology company developing small molecule therapeutics for rare tumors and aggressive cancers.

Advancing biopsy specimen stewardship and expanding access to precision oncology.

Leveraging quantum mechanics for accelerated molecular simulations in drug discovery.

Pioneering next-generation bispecific ADCs for cancer treatment.

Developing disease-responsive advanced therapies through programmable gene control technology.

Atomwise uses AI to accelerate the discovery of novel small molecule therapeutics with its AtomNet platform.